EDGAR·FLOW

MetaVia Inc. — Form 8-K

Filed November 16, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 72/100
What the filing says
MetaVia presented preclinical mouse study data on November 14, 2026, showing DA-1726 (a GLP1R/GCGR dual agonist) achieved weight loss comparable to retatrutide (43.6% vs 41.7% at high dose) with less appetite suppression (41.4% vs 31.2% food intake reduction), greater glucose lowering (39.2% vs 32.5%), and significantly increased hepatic FGF21 expression (p<0.05 for gene, p<0.001 for circulating protein). The company plans to initiate a Phase 2, 48-week non-biopsy study in MetALD and ALD in H2 2027, building on Phase 1 Part 3B data showing 13.5% placebo-adjusted weight loss and 68.0% liver fat reduction.
Why this rating

Preclinical data de-risks Phase 2 initiation for lead asset at $3M-market-cap biotech; favorable differentiation vs. competitor compound strengthens clinical rationale, though early-stage risk remains.

Tradability signal
NO TRADE

No trade: only ~$0k traded in the last 30 min — too illiquid to enter and exit. (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it positive)
before filing · preread
$1.27 ▼ 0.78%
at our read · unknown
$1.28
+10 min · unknown
$1.27 ▼ 0.78%
+30 min · unknown
$1.28 ▲ 0.39%
+1 hr · unknown
$1.26 ▼ 1.56%
+4 hrs · unknown
$1.29 ▲ 0.78%

The stock had already moved +0.79% between hitting EDGAR and our read finishing — deltas above are measured from our read.

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ MTVA · stock on Yahoo Finance ↗

See more from November 16, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.